Cargando…

Survival benefits of oral anticoagulants in patients with pulmonary arterial hypertension: Protocol for a systematic review and meta-analysis

BACKGROUND: Pulmonary arterial hypertension (PAH) is an incurable disease with high mortality. Although most studies recommend anticoagulation treatment for idiopathic pulmonary arterial hypertension (IPAH), the survival benefits are uncertain. Therefore, the present paper provides a protocol to inv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Hai-Chao, Wang, Na, Zhang, Wen, Gu, Zhi-Chun, Liu, Xiao-Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133434/ https://www.ncbi.nlm.nih.gov/pubmed/30200129 http://dx.doi.org/10.1097/MD.0000000000012203

Ejemplares similares

Overdue to understand anticoagulation in pulmonary arterial hypertension
por: Parikh, Kishan S., et al.
Publicado: (2018)

Are anticoagulants still indicated in pulmonary arterial hypertension?
por: Olschewski, Horst, et al.
Publicado: (2018)

Survival benefits of warfarin in Korean patients with idiopathic pulmonary arterial hypertension
por: Kang, Byung Ju, et al.
Publicado: (2015)

Net clinical benefit analysis of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: Protocol for a systematic review and meta-analysis
por: Shen, Nan-Nan, et al.
Publicado: (2019)

Anticoagulation in pulmonary arterial hypertension: a decision analysis
por: Jose, Arun, et al.
Publicado: (2019)

The safety of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension: Protocol for a systemic review and network meta-analysis
por: Gu, Zhi-Chun, et al.
Publicado: (2018)

Benefits of Curcumin in the Vasculature: A Therapeutic Candidate for Vascular Remodeling in Arterial Hypertension and Pulmonary Arterial Hypertension?
por: Li, Ke-Xue, et al.
Publicado: (2022)

Use of direct oral anticoagulants for chronic thromboembolic pulmonary hypertension
por: Gavilanes-Oleas, Francisca Alexandra, et al.
Publicado: (2018)

Complications associated with the use of oral anticoagulation in patients with pulmonary arterial hypertension from two referral centers
por: Roldan, Tamara, et al.
Publicado: (2017)

Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol
por: Calderone, Alicia, et al.
Publicado: (2016)

The impact of pulmonary arterial hypertension-targeted therapy on survival in Chinese patients with idiopathic pulmonary arterial hypertension
por: Zeng, Wei-Jie, et al.
Publicado: (2012)

The limits of oral therapy in pulmonary arterial hypertension management
por: Liu, Qian-Qian, et al.
Publicado: (2015)

Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry
por: Said, Karim
Publicado: (2014)

Meta-Analysis of Pulmonary Artery Denervation for Treatment of Pulmonary Hypertension
por: Zuo, Wanyun, et al.
Publicado: (2022)

Real-World Prevalence of Direct Oral Anticoagulant Off-Label Doses in Atrial Fibrillation: An Epidemiological Meta-Analysis
por: Shen, Nan-Nan, et al.
Publicado: (2021)

A case report of pulmonary arterial hypertension in pregnancy and complications of anticoagulation therapy
por: Xiang, Yangfang, et al.
Publicado: (2018)

Kidney Transplantation Confers Survival Benefit for Candidates With Pulmonary Hypertension
por: Nguyen, Michelle C., et al.
Publicado: (2021)

Net Clinical Benefit of Direct Oral Anticoagulants in Patients With Cancer and Venous Thromboembolism: A Systematic Review and Trade-Off Analysis
por: Yan, Yi-Dan, et al.
Publicado: (2020)

Benefits from the Early Initiation of Macitentan for Pulmonary Arterial Hypertension
por: Jung, Hae Ok
Publicado: (2018)

Direct Oral Anticoagulants vs. Vitamin-K Antagonists in the Elderly With Atrial Fibrillation: A Systematic Review Comparing Benefits and Harms Between Observational Studies and Randomized Controlled Trials
por: Shen, Nan-Nan, et al.
Publicado: (2020)

Therapeutic Benefits of Induced Pluripotent Stem Cells in Monocrotaline-Induced Pulmonary Arterial Hypertension
por: Huang, Wei-Chun, et al.
Publicado: (2016)

BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis
por: Evans, Jonathan D W, et al.
Publicado: (2016)

Kidney Transplantation Confers Survival Benefit for Candidates With Pulmonary Hypertension: Erratum
Publicado: (2023)

Direct oral anticoagulants in patients with chronic thromboembolic pulmonary hypertension and the presence of recent thrombus during pulmonary endarterectomy
por: Jeong, Ina, et al.
Publicado: (2022)

Comparison of effectiveness and safety of direct oral anticoagulants versus vitamin-k antagonists in elderly patients with atrial fibrillation: a systematic review and cost-effectiveness analysis protocol
por: Wang, Na, et al.
Publicado: (2020)

Pulmonary hypertensive crisis in children with pulmonary arterial hypertension undergoing cardiac catheterization
por: Li, Qiangqiang, et al.
Publicado: (2022)

Effectiveness and Safety of Under or Over-dosing of Direct Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-analysis of 148909 Patients From 10 Real-World Studies
por: Shen, Nan-Nan, et al.
Publicado: (2021)

Leptin levels predict survival in pulmonary arterial hypertension
por: Tonelli, Adriano R., et al.
Publicado: (2012)

Optimal length of oral anticoagulant treatment for maximum benefit within 5 years after discontinuation of oral anticoagulants in patients with acute pulmonary embolism who require secondary thromboprophylaxis
por: Zhao, Yunfeng, et al.
Publicado: (2023)

Oral treprostinil improves pulmonary vascular compliance in pulmonary arterial hypertension
por: Khan, Akram, et al.
Publicado: (2022)

Direct oral anticoagulants for extended thromboprophylaxis in medically ill patients: meta-analysis and risk/benefit assessment
por: Al Yami, Majed S, et al.
Publicado: (2018)

Clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis
por: Wang, Dayang, et al.
Publicado: (2023)

Cardiac amyloidosis presenting as pulmonary arterial hypertension: A case report
por: Gao, Ming, et al.
Publicado: (2023)

Statins Have No Additional Benefit for Pulmonary Hypertension: A Meta-Analysis of Randomized Controlled Trials
por: Wang, Lin, et al.
Publicado: (2016)

Effects of oral targeted treatments in pulmonary arterial hypertension: A systematic review and meta-analysis
por: Zhu, Hui-ru, et al.
Publicado: (2022)

Association Between Anticoagulation Outcomes and Venous Thromboembolism History in Chronic Thromboembolic Pulmonary Hypertension
por: Zhu, Yong-Jian, et al.
Publicado: (2021)

Benefit, Risk and Cost in Oral Anticoagulation for Stroke Prevention: Is It the Third Factor?
por: Choi, Jong-Il
Publicado: (2019)

Balancing the benefits and harms of oral anticoagulation in non-valvular atrial fibrillation
por: Lindley, Richard I
Publicado: (2021)

Atrial Fibrillation, Oral Anticoagulants, and Concomitant Active Cancer: Benefits and Risks
por: Atterman, Adriano, et al.
Publicado: (2021)

Oral Anticoagulant and Antiplatelet Therapy for Peripheral Arterial Disease: A Meta-analysis of Randomized Controlled Trials
por: Tang, Tao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dliujrk8a3376qrsdp40d3u67d